Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Alexza Pharmaceuticals
November 12, 2014
Debt-funded biotechs under the spotlight
May 09, 2013
Teva partnership marks a reversal of fortune for Alexza
January 02, 2013
Pharma regulatory news over the Christmas period
May 04, 2012
Alexza faces cash squeeze as Adasuve sent another Dear John letter
December 13, 2011
Alexza's failure to win broad backing for Adasuve could be last gasp
February 02, 2011
Regulatory worries dampen enthusiasm for Map's Levadex deal
October 13, 2010
Alexza investors right to be agitated over FDA rebuff
September 20, 2010
Event - Alexza hopes for unhindered approval of inhaled antipsychotic
August 27, 2010
Cypress risks deepening disquiet with another spending spree
July 28, 2010
First half 2010 sees a return to more conventional deal values
June 22, 2010
Biovail and Valeant join forces to drive growth
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
July 28, 2022
Access Valuable Insights Payer Behaviour Infographic
July 18, 2022
Medtech - Going steady
Editor's Picks
July 27, 2022
Aids 2022 preview – Gilead shoots for an HIV cure
July 21, 2022
Private equity gets serious about drug development
July 18, 2022
Unpacking Royalty Pharma
July 19, 2022
No plain sailing for Novartis’s PD-1 plan
July 26, 2022
Move over Aduhelm, it’s tofersen’s turn
